Phase I: relapsed or refractory B-cell malignancies

Clinical trials for Phase I: relapsed or refractory B-cell malignancies explained in plain language.

Never miss a new study

Get alerted when new Phase I: relapsed or refractory B-cell malignancies trials appear

Sign up with your email to follow new studies for Phase I: relapsed or refractory B-cell malignancies, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Not yet finished but already full! 1

New hope for chinese patients with Hard-to-Treat blood cancers

Disease control Ongoing

This study tests a drug called acalabrutinib in Chinese adults with certain blood cancers (mantle cell lymphoma, chronic lymphocytic leukemia, or other B-cell cancers) that have come back or not responded to treatment. The trial has two parts: the first checks safety and how the …

Matched conditions: PHASE I: RELAPSED OR REFRACTORY B-CELL MALIGNANCIES

Phase 1/2 • Sponsor: AstraZeneca • Aim: Disease control

Last updated Jun 27, 2026 12:09 UTC

Phase I: relapsed or refractory B-cell malignancies

Get alerted when new Phase I: relapsed or refractory B-cell malignancies trials appear

New hope for chinese patients with Hard-to-Treat blood cancers